MIP Discovery, a developer of non-biological affinity reagents designed to accelerate the production of cell and gene therapies, has closed a £7 million Series A financing round, led by Mercia Ventures.
We caught up with Kevin Knopp, CEO and co-founder of 908 Devices, to discuss the main obstacles in cell and gene therapy manufacturing and how the company's recent partnership with Terumo Blood and Cell Technologies is tackling these challenges.
Avid Bioservices, a biologics contract development and manufacturing organization (CDMO), has completed construction of several CGMP manufacturing suites within its new and gene therapy (CGT) development and CGMP manufacturing facility.
ScaleReady, a cell therapy manufacturing company, and CTMC, a joint venture between National Resilience and the MD Anderson Cancer Center, have entered into a new collaborative partnership
AGC Biologics, a global contract development and manufacturing organization (CDMO), has completed the expansion of its manufacturing space at its Milan Cell and Gene Center of Excellence production site.
Cytiva and the life sciences business of Pall Corporation are now united as one business under the Cytiva brand, with the completion of the integration announced this morning. Emmanuel Ligner, Danaher Group Executive, President and CEO of Cytiva, tells...
Despite an uncertain macroeconomic environment, Lonza says its ‘resilient’ business model and sustained market demand delivered a strong financial performance in 2022, in line with the Swizterland based CDMO’s outlook.
